This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by VAN VLIET, G. Search for Related Content PubMed PubMed Citation Articles by VAN VLIET, G.

Growth Hormone (GH) Response to a Single Intravenous Injection of Synthetic GH-Releasing Hormone in Prepubertal Children with Growth Failure

Address requests for reprints to: P. Chatelain, INSERM U34, Hôpital Debrousse, 29 rue Soeur Bouvier, 69322 Lyon, France.

In this collaborative study involving 27 European medical centers, the plasma GH response to a single iv bolus dose of 2 µ/kg BW synthetic GHRH-(1–44) NH₂ was determined in 574 children with growth failure of various etiologies. Analysis of the plasma GH response to GHRH was performed in 394 validated prepubertal children; these children were subdivided into 3 groups according to the degree of GH deficiency assessed within 6 months by conventional provocative tests (insulin, arginine, etc.): normal GH status (n = 210), partial GH deficiency (n = 73), or severe GH deficiency (n = 111).

The mean peak GH values (±2 SEM) after GHRH treatment in the three groups were 45.8 ± 4.8, 29.2 ± 6.3, and 16.8 ±3.1 µU/mL, respectively, and were greater than those after the conventional tests. The GH responses were consistent with the degree of GH deficiency based on the responses to the conventional tests. In addition, the areas under the GH response curves in the three groups were significantly different (P < 0.0001). Among children with severe idiopathic GH deficiency 77% had a peak plasma GH level after GHRH above 10.0 µU/mL and 39% had a peak GH above 20.0 µU/mL. In these children, a single GHRH injection provides information on both their GH secretory capacity and the putative supresellar etiology of their GH deficiency, and may be of potential therapeutic value.

^* See Appendix A for list of investigators and committees.

Received November 4, 1986.

This article has been cited by other articles:

				J.-C. Carel, J.-P. Tresca, M. Letrait, J.-L. Chaussain, Y. Lebouc, J.-C. Job, and J. Coste Growth Hormone Testing for the Diagnosis of Growth Hormone Deficiency in Childhood: A Population Register-Based Study J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2117 - 2121. [Abstract] [Full Text] [PDF]